Infinity discontinues IPI-504
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) discontinued development of IPI-504 to treat breast cancer based on an interim review of data from HER2-positive metastatic breast cancer patients enrolled in the first cohort of a Phase II trial. The company said IPI-504 plus Herceptin trastuzumab displayed clinical activity that was insufficient to continue the study, which the company believes was a result of the small molecule Hsp90 inhibitor being administered at a less than optimal dose. Infinity said it will continue to evaluate IPI-504 in two ongoing studies to treat advanced non-small cell lung cancer (NSCLC): IPI-504 alone in a Phase II trial and in combination with Taxotere docetaxel in a Phase Ib trial. The company does not plan to conduct any new trials at this time. Infinity was up $0.26 to $6.15 on Wednesday. ...